•
Sep 30, 2023

Erasca Q3 2023 Earnings Report

Reported financial results for the third quarter of 2023 and provided business updates.

Key Takeaways

Erasca reported a net loss of $30.4 million, or $(0.20) per share, for the quarter ended September 30, 2023. The company's cash, cash equivalents, and marketable securities were $343.6 million as of September 30, 2023, which is expected to fund operations into the second half of 2025.

First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib.

Identified promising activity in HERKULES-3 signal-seeking study of ERAS-007 in combination with encorafenib and cetuximab in EC-naïve patients with BRAFm CRC.

Multiple upcoming catalysts across ongoing clinical programs.

Strong balance sheet with cash, cash equivalents, and marketable securities of $344 million as of September 30, 2023.

Total Revenue
$0
EPS
-$0.2
Previous year: -$0.29
-31.0%
Gross Profit
-$941K
Cash and Equivalents
$344M
Previous year: $365M
-6.0%
Free Cash Flow
-$24.4M
Previous year: -$25.7M
-5.4%
Total Assets
$419M
Previous year: $446M
-6.1%

Erasca

Erasca

Forward Guidance

Erasca expects its current cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2025.

Positive Outlook

  • Ability to execute on the upcoming near-term catalysts for our clinical programs
  • Potential therapeutic benefits and safety profile of our product candidates, including naporafenib, ERAS-007, ERAS-601, and ERAS-801
  • Planned advancement of our development pipeline, including the anticipated timing of the first patient dosing in the SEACRAFT-2 trial
  • Anticipated timing of data readouts for the SEACRAFT-1, HERKULES-3, FLAGSHP-1, and THUNDERBBOLT-1 trials, and other upcoming development milestones
  • Expectation that our current cash, cash equivalents, and marketable securities will fund our operations into the second half of 2025

Challenges Ahead

  • Approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach
  • Potential delays in the commencement, enrollment, data readouts, and completion of clinical trials and preclinical studies
  • Dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing
  • Unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims
  • Unfavorable results from preclinical studies or clinical trials